Lokren 20mg 28 tablets — Made in France — Free Delivery

Brand: VEVICU
Product Code: Lokren
Availability: 2 - 3 Days

$200.00

Add to Cart

Description

Indications.

Treatment of arterial hypertension.

Prevention of angina attacks.

Contraindications.

Hypersensitivity to betaxolol or to any other component of the preparation.

Severe forms of bronchial asthma and chronic obstructive pulmonary disease.

Heart failure not controlled by treatment.

Cardiogenic shock.

Blockade II and III degree in patients without a pacemaker.

Prinzmetal's angina (monotherapy with the preparation is contraindicated in the isolated / typical form of this disease).

Sinus node dysfunction (including sinoatrial block).

Bradycardia (heart rate <45-50 bpm).

Severe forms of Raynaud's syndrome and other peripheral arterial diseases.

Untreated pheochromocytoma.

Arterial hypotension.

History of anaphylactic reactions.

metabolic acidosis.

The preparation is contraindicated for use in combination with floktafenin and sultopride (see Section "Interaction with other medicinal products and other forms of interaction").

Compound

active ingredient: betaxolol;

1 tablet contains betaxolol hydrochloride 20 mg

excipients: lactose, microcrystalline cellulose, sodium starch (type A), colloidal silicon dioxide, magnesium stearate

shell: hypromellose, titanium dioxide (E 171), polyethylene glycol.

Method of application and dose.

The preparation is intended for oral use.

The usual dose for the treatment of arterial hypertension and for the prevention of angina attacks is 1 tablet of 20 mg once a day. The calendar pack, which has the days of the week on it, provides the best conditions for treatment, making it easier for the patient to follow the instructions for taking the medicine.

Dosing for patients with renal insufficiency.

The dose must be adjusted depending on the state of the patient's kidney function.

With QC ³ 20 ml / min, dose adjustment is not required. However, it is recommended to conduct clinical observation from the start of therapy until equilibrium levels of the preparation in the blood are reached (on average 4 days).

For patients with severe renal insufficiency (creatinine clearance <20 ml / min), the recommended initial dose is 10 mg per day (regardless of the frequency and schedule of dialysis procedures in patients undergoing hemodialysis).

Dosage for patients with hepatic insufficiency.

There is no need to adjust the dose; however, clinical observation is recommended at the beginning of therapy.

Children. The safety and efficacy of the preparation in children have not been established, so its use in this category of patients is contraindicated.

0 reviews

There are no reviews for this product.